A Treatment Option in Myelofibrosis

This OncLive webinar will be bringing you the following learning objectives/takeaways:
Clinical data supporting a treatment option for patients with intermediate-2 or high risk myelofibrosis
NCCN Clinical Practice Guidelines surrounding use of the new treatment option in myelofibrosis
Safety, adverse event management, and dose modifications
Steps for starting your patients on this treatment option
Speaker:
Dr. Bart Scott
Assistant Professor, Oncology
University of Washington School of Medicine
Bart Scott, M.D., is a board certified oncologist at SCCA, an assistant member of the Fred Hutchinson Cancer Research Center and a UW assistant professor of Oncology.
Dr. Scott’s area of expertise is myelodysplastic syndrome and myeloproliferative disorders. He believes that patients should be the principal decision makers regarding their care. He thinks it is very important to respect the desire and wishes of each individual patient.
Dr. Scott earned his M.D. at the UW. His interests include clinical trial development in patients with myeloid malignancies.
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive